Corrigendum to “Pazopanib in the treatment of advanced renal cell carcinoma” by David Cella and Jennifer L. Beaumont,Therapeutic Advances in Urology,2016,Vol. 8(1) 61–69. DOI: 10.1177/1756287215614236

Page 65, column 2, lines 7–13

The following text did not appear correctly in the article:

“OS for the favorable/intermediate prognostic groups (according to MSKCC criteria) was not reached (NR)/12 months while PFS was 25/17 months. For the favorable/intermediate prognostic groups as assessed according to Heng criteria, OS was NR/12 months while PFS was NR/25 months.”

The correct text reads as follows:

“PFS for the favorable/intermediate prognostic groups (according to MSKCC criteria) was not reached (NR)/12 months while OS was 25/17 months. For the favorable/intermediate prognostic groups as assessed according to Heng criteria, PFS was NR/12 months while OS was NR/25 months.”

The authors apologize for this error in their submission.